At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 73 enrolled
Drug / intervention
MEN1703drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of SEL24 in Patients With Acute Myeloid Leukemia
In Brief
A Phase 2 clinical trial evaluating MEN1703 for Acute Myeloid Leukemia. Completed, enrolled 73 participants across 15 sites in 4 countries.
Detailed Summary
The purpose of the clinical trial is to identify the maximum tolerated dose of MEN1703 and to further investigate its safety profile in participants with acute myeloid leukemia (AML).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesItaly, Poland, Spain, United States
CollaboratorsMedpace, Inc., Theradex
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartMar 2017
Primary CompletionApr 2023
TodayJul 2026
First PostedJan 2, 2017
Enrollment StartMar 10, 2017
Primary CompletionApr 13, 2023
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 9.5 years ago
Interventions
MEN1703drug
MEN1703 given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.